Increase in frequency of bladder cancer followed by rapid development of therapeutics related to it are holding the responsibility of growth of global bladder cancer therapeutics market.
Research states that those witnessing a delay of more than 9 months for bladder cancer detection are at a higher risk of succumbing to bladder cancer. Awareness campaigns focus on educating about the symptoms, so that patients can get diagnosed on time to avoid untimely deaths.
The companies operating in bladder cancer therapeutics industry are working toward usage of nanobots for improving therapeutic efficacy of bladder cancer’s intravesical treatment. They are also exploring combining two anti-cancer drugs to avoid the application of standard chemotherapy.
Bladder cancer means an unusual growth of cells in bladder. As of now, chemotherapy, surgery, and radiation are the methods used to cure bladder cancer. However, research is being conducted to have bladder cancer drugs in place, so as to avoid the side-effects caused by the methods mentioned above.
Types of bladder cancer include urothelial carcinoma, adenocarcinoma, squamous cell bladder cancer, and likewise. As per the American Society of Clinical Oncology (ASCO), urothelial carcinoma accounts for almost 90% of all types of bladder cancers.
The last few years have seen a marked rise in awareness regarding bladder diseases and the therapies available. In March 2022, the World Bladder Cancer Patient Coalition declared the theme called “Don’t Go Red” to send across the message that detection at an early stage is critical to enhance quality of life and long-term survival.
Initiatives like these are important as The Global Cancer Observatory states that prostate and bladder cancer are amongst the top 10 high incidence cancers across the globe.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the World Cancer Research Fund International, 573,000 new cases of bladder cancer were registered worldwide in the year 2020. This is ascribed to unhealthy habits such as smoking.
This cancer can also be seen in those who have a history of bladder cancer. In this case, it is observed in people aged 55 and above. Increase in geriatric population is thus another factor catalyzing the bladder cancer therapeutics market.
As per the WHO, the number of people aged 60 and above had outnumbered children aged 5 and below. It further states that the percentage of aged population globally will reach 22% between 2015 and 2050.
Exponential rise in geriatric population is thus propelling bladder cancer therapeutics market opportunities.
The global bladder cancer therapeutics market is witnessing an influx of new target therapeutics, thereby accelerating its scope.
For instance, in February 2022, Astellas Pharma Inc., along with Seagen Inc., reported the preliminary findings from Cohort H of EV-103 study, which has been testing PADCEV (enfortumab vedotin-jeff) as one of the monotherapies in patients with MIBC who have been ineligible for cisplatin-based treatment.
In April 2024, the U.S. FDA approved ImmunityBio’s combination therapy meant for treating a kind of bladder cancer.
In August 2021, the U.S. FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for adjuvant treatment of those suffering from urothelial carcinoma (UC).
On May 7, 2024, new intravesical targeted drug delivery system meant for patients contracting bladder cancer showed positive results in Phase I trial conducted by Johnson & Johnson. The aim of the study is to assess efficacy and safety regarding TAR-210 as one of the delivery methods for local, sustained release of erdafitinib into bladder.
Continual development of advanced target therapeutics for bladder cancer are thus bladder cancer therapeutics market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest bladder cancer therapeutics market analysis, North America held the largest share of immunotherapy for bladder cancer landscape in 2023 and the situation is expected to remain unchanged during the forecast period.
This is attributed to a noticeable rise in cases of bladder cancer in the U.S. As per the American Cancer Society (January 2022 updates), nearly 81,180 new-fangled cases of bladder cancer were reported in 2022.
Asia Pacific’s significant bladder cancer therapeutics market growth is due to adoption of upgraded diagnostic as well as treatment options regarding bladder cancer by the countries such as India and China. India alone is home to ~19,000 bladder cancer cases as of now.
Latin America is also expected to witness a robust CAGR with respect to bladder cancer therapeutics market in the near future. This is owing to Brazil housing a sizable number of individuals suffering from bladder cancer. As per the WHO, Brazil has ~9500 cases of bladder cancer as of now.
The bladder cancer therapeutics market manufacturers are launching new products and the regulatory bodies are expediting their approval. For instance, in January 2020, Merck and Pfizer announced that the U.S. FDA had approved PD-L1 inhibitor Bavencio derived out of their collaboration.
The bladder cancer therapeutics market report highlights Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, AstraZeneca, Johnson & Johnson, Pfizer Inc., Novartis AG, Eli Lilly and Company, Sanofi S.A., and Genentech, Inc. based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 271.4 Mn |
| Market Forecast (Value) in 2034 | US$ 456.3 Mn |
| Growth Rate (CAGR) | 4.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 271.4 Mn in 2023
It is projected to grow at a CAGR of 4.8% from 2024 to 2034
Growing prevalence of bladder cancer and development of new target therapeutics
Cancer research institutes accounted for the largest share in 2023
North America was the dominant region in 2023
Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, AstraZeneca, Johnson & Johnson, Pfizer Inc., Novartis AG, Eli Lilly and Company, Sanofi S.A., and Genentech, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Bladder Cancer Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bladder Cancer Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Type of Treatment
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Treatment, 2020-2034
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Targeted Therapy
6.3.4. Surgery
6.3.5. Radiation Therapy
6.3.6. Others (Combination Therapy, etc.)
6.4. Market Attractiveness, by Type of Treatment
7. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Type of Bladder Cancer
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
7.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
7.3.2. Muscle Invasive Bladder Cancer (MIBC)
7.4. Market Attractiveness, by Type of Bladder Cancer
8. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Intravenous
8.3.3. Intravesical
8.4. Market Attractiveness, by Route of Administration
9. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Ambulatory Surgical Centers
9.3.4. Cancer Research Institutes
9.4. Market Attractiveness, by End-user
10. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Bladder Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Treatment, 2020-2034
11.2.1. Chemotherapy
11.2.2. Immunotherapy
11.2.3. Targeted Therapy
11.2.4. Surgery
11.2.5. Radiation Therapy
11.2.6. Others (Combination Therapy, etc.)
11.3. Market Attractiveness, by Type of Treatment
11.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
11.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
11.4.2. Muscle Invasive Bladder Cancer (MIBC)
11.5. Market Attractiveness, by Type of Bladder Cancer
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Oral
11.6.2. Intravenous
11.6.3. Intravesical
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Ambulatory Surgical Centers
11.8.4. Cancer Research Institutes
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Type of Treatment
11.11.2. By Type of Bladder Cancer
11.11.3. By Route of Administration
11.11.4. By End-user
11.11.5. By Country
12. Europe Bladder Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Treatment, 2020-2034
12.2.1. Chemotherapy
12.2.2. Immunotherapy
12.2.3. Targeted Therapy
12.2.4. Surgery
12.2.5. Radiation Therapy
12.2.6. Others (Combination Therapy, etc.)
12.3. Market Attractiveness, by Type of Treatment
12.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
12.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
12.4.2. Muscle Invasive Bladder Cancer (MIBC)
12.5. Market Attractiveness, by Type of Bladder Cancer
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Oral
12.6.2. Intravenous
12.6.3. Intravesical
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Ambulatory Surgical Centers
12.8.4. Cancer Research Institutes
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Type of Treatment
12.11.2. By Type of Bladder Cancer
12.11.3. By Route of Administration
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Bladder Cancer Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Treatment, 2020-2034
13.2.1. Chemotherapy
13.2.2. Immunotherapy
13.2.3. Targeted Therapy
13.2.4. Surgery
13.2.5. Radiation Therapy
13.2.6. Others (Combination Therapy, etc.)
13.3. Market Attractiveness, by Type of Treatment
13.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
13.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
13.4.2. Muscle Invasive Bladder Cancer (MIBC)
13.5. Market Attractiveness, by Type of Bladder Cancer
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Oral
13.6.2. Intravenous
13.6.3. Intravesical
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Ambulatory Surgical Centers
13.8.4. Cancer Research Institutes
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Type of Treatment
13.11.2. By Type of Bladder Cancer
13.11.3. By Route of Administration
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Bladder Cancer Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Treatment, 2020-2034
14.2.1. Chemotherapy
14.2.2. Immunotherapy
14.2.3. Targeted Therapy
14.2.4. Surgery
14.2.5. Radiation Therapy
14.2.6. Others (Combination Therapy, etc.)
14.3. Market Attractiveness, by Type of Treatment
14.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
14.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
14.4.2. Muscle Invasive Bladder Cancer (MIBC)
14.5. Market Attractiveness, by Type of Bladder Cancer
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Oral
14.6.2. Intravenous
14.6.3. Intravesical
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Ambulatory Surgical Centers
14.8.4. Cancer Research Institutes
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Type of Treatment
14.11.2. By Type of Bladder Cancer
14.11.3. By Route of Administration
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Bladder Cancer Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type of Treatment, 2020-2034
15.2.1. Chemotherapy
15.2.2. Immunotherapy
15.2.3. Targeted Therapy
15.2.4. Surgery
15.2.5. Radiation Therapy
15.2.6. Others (Combination Therapy, etc.)
15.3. Market Attractiveness, by Type of Treatment
15.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
15.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
15.4.2. Muscle Invasive Bladder Cancer (MIBC)
15.5. Market Attractiveness, by Type of Bladder Cancer
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Oral
15.6.2. Intravenous
15.6.3. Intravesical
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Ambulatory Surgical Centers
15.8.4. Cancer Research Institutes
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Type of Treatment
15.11.2. By Type of Bladder Cancer
15.11.3. By Route of Administration
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Merck & Co., Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Bristol-Myers Squibb Company
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. AstraZeneca
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Johnson & Johnson
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Pfizer Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Eli Lilly and Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sanofi S.A.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Genentech, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
Table 02: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
Table 03: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 04: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 05: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 06: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 07: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
Table 08: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
Table 09: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 11: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
Table 13: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
Table 14: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 15: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
Table 18: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
Table 19: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 20: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 21: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
Table 23: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
Table 24: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 25: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
Table 28: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
Table 29: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 30: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Bladder Cancer Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034
Figure 02: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by Type of Treatment, 2023
Figure 03: Global Bladder Cancer Therapeutics Market Value Share, by Type of Treatment, 2023
Figure 04: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by Type of Bladder Cancer, 2023
Figure 05: Global Bladder Cancer Therapeutics Market Value Share, by Type of Bladder Cancer, 2023
Figure 06: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023
Figure 07: Global Bladder Cancer Therapeutics Market Value Share, by Route of Administration, 2023
Figure 08: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by End-user, 2023
Figure 09: Global Bladder Cancer Therapeutics Market Value Share, by End-user, 2023
Figure 10: Global Bladder Cancer Therapeutics Market Value Share, by Region, 2023
Figure 11: Global Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
Figure 12: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 13: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 14: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
Figure 15: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
Figure 16: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by End-user, 2023
Figure 19: Global Bladder Cancer Therapeutics Market Value Share, by End-user, 2023
Figure 20: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 26: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
Figure 27: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 28: North America Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 30: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
Figure 31: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 32: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 37: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
Figure 38: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 39: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 41: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
Figure 42: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 43: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 48: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
Figure 49: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 52: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
Figure 53: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 54: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 59: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
Figure 60: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 61: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 63: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
Figure 64: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 65: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 70: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
Figure 71: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 74: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
Figure 75: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 76: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Bladder Cancer Therapeutics Market
